Evaluating the sinus and Nasal Quality of Life Survey in the pediatric cystic fibrosis patient population. (November 2017)

• Record Type: Journal Article
• Authors: Xie, Deborah X.; Wu, Jeffanie; Kelly, Katherine; Brown, Rebekah F.; Shannon, Chevis; Virgin, Frank W.
• Is Part Of: International journal of pediatric otorhinolaryngology. Volume 102(2017:Nov.)
• Page Start: 133
• Page End: 137
• Publication Date: 2017-11
• Subjects: Cystic fibrosis -- Quality of life -- Chronic rhinosinusitis -- SN-5; Otolaryngology -- Periodicals; Pediatrics -- Periodicals; Otolaryngology -- Periodicals; Pediatrics -- Periodicals; Oto-rhino-laryngologie -- Périodiques; Pédiatrie -- Périodiques; 618.9209751
• DOI: 10.1016/j.ijporl.2017.09.014
• Languages: English
• ISSNs: 0165-5876

Abstract

Abstract: Introduction: The Sinus and Nasal Quality of Life Survey (SN-5) is a validated quality of life (QOL) questionnaire for chronic rhinosinusitis in patients age 2–12. Its utility in the cystic fibrosis (CF) has been studied, but not yet validated. The purpose of this study is to determine the effectiveness of the SN-5 for evaluation of sinonasal symptoms in the pediatric CF population. Methods: This retrospective study analyzed SN-5 surveys completed between 2012 and 2015 by pediatric CF patients and caregivers. Baseline and follow-up overall QOL scores and specific symptom scores were obtained from surveys completed in the three-year span. Non-parametric statistics were conducted to identify differences in survey data. Results: A total of 165 patients completed baseline and follow-up surveys. The overall QOL of the patient cohort did not change over the duration of the study (p = 0.660). Thirty-seven patients indicated higher overall QOL, with all five symptom scores showing significant improvement. Analysis by age group showed that QOL was significantly correlated with all five symptoms for children ages 0–4. In patients 5–12 years, overall QOL was only correlated with sinus infection (r = −0.3090, p = 0.01). QOL was significantly correlated with sinus infection (r = −0.2903, p = 0.04) and allergy symptoms (r = −0.5644, p < 0.01) in patients >12 years of age. Conclusion: There remains a need for a validated CRS QOL tool for children with CF. Though the SN-5 has previously been described as a potential instrument, our data suggest that it may be more valuable in children ages 0–4.